Trial Profile
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 07 Sep 2022 Planned End Date changed from 31 Oct 2025 to 1 Oct 2026.
- 07 Sep 2022 Planned primary completion date changed from 31 Oct 2022 to 1 Oct 2024.
- 18 Jan 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Oct 2022.